Can your setting shape a psychedelic trip? new study investigates
NCT ID NCT06626139
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a person's mindset and physical environment (called 'set and setting') influence the effects of psilocybin, a psychedelic compound. Researchers will give 120 healthy adults aged 21-70 with lower-than-average mental well-being either psilocybin or a placebo in different settings. The goal is to understand how these factors affect challenging experiences and changes in well-being and connectedness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Nov 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
If you are interested in participating in this study, please follow this link to check your eligibility: https://tiny.ucsf.edu/setsettingscreener Inclusion Criteria: Participants will be considered for inclusion if they: 1. Are between 21 and 70 years of age 2. Are fluent in speaking and reading English 3. Are able to swallow pills/capsules 4. If able to become pregnant, must be non-lactating, have a negative pregnancy test at study entry and prior to each Experimental Session and must agree to an adequate form of birth control over the course of the study. Adequate forms of birth control include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e., condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). Unable to become pregnant is defined as documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, and/or tubal ligation), permanently sterile by medical device such as Essure, postmenopausal, or assigned male sex at birth. 5. Able and willing to provide informed consent 6. Able and willing to use computers and tablets or phones to enter electronic data 7. Agree to inform the investigators within 48 hours of any new or changed medical conditions. 8. Have an identified support person 9. For those dosed with psilocybin, their prior consent to be accompanied home (or to an otherwise safe destination) by a support person, chosen by them - ahead of time, or by a member of the study team. 10. Willing to provide contact details for a friend or family member, should there be an inability to make direct contact with the participant Exclusion Criteria: Participants will be excluded if they: 1. Have a current diagnosed psychiatric disorder that, in the opinion of the study clinician or PI, renders to person psychologically unstable or unduly vulnerable, or interferes with activities of daily living, or could impact attendance at or participation in study activities 2. Have a medically significant condition that renders the person unsuitable for the study 3. Give a positive alcohol breathalyzer test result on any study visit 4. A positive urine drug screen to any excluded substances prior to an Experimental Session, which warrants exclusion based on concerns that it may compromise safety or confound outcomes 5. Are breastfeeding, or have a positive pregnancy test at screening or at any point during the course of the study 6. Systolic and diastolic BP values exceeding 139 SBP and exceeding 89 DBP and heart rate exceeding 90 bpm would result in exclusion from the study. 7. Present with a exceeding 450 msec or with evidence of cardiac damage, ischemia, or heart disease. 8. Have received an investigational drug within 30 days of the screening visit 9. Have an allergy or intolerance to any of the materials contained in either drug product or setting components, such as certain scents. 10. Have MRI contraindications (e.g., metal implants, pacemakers, claustrophobia etc.) 11. Have any current problem which, in the opinion of the investigator or clinician, might interfere with participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy participants with lower-than-average mental well-being are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UCSF Mission Bay
RECRUITINGSan Francisco, California, 94158, United States